292 results about "Claudin" patented technology

The invention discloses lactobacillus plantarum for relieving diarrhea caused by ETEC and application of the lactobacillus plantarum, and belongs to the technical field of microorganisms. The lactobacillus plantarum CCFM8661 with the effect of relieving the diarrhea caused by the ETEC is screened out, and the lactobacillus plantarum CCFM8661 is specifically embodied in that the weight loss of mice with the diarrhea caused by the ETEC and the increase of the water content of excrement are relieved; the content of pro-inflammatory cytokines IL-1beta, IFN-gamma, IL-6 and IL-8 in serum is obviously reduced; the content of immune factors IgA, IgG and IgM in serum is obviously increased; sT is reduced, and the level of AQP3 is increased; jejunum injury is relieved, and jejunum villus length shortening and crypt depth increasing caused by ETEC are remarkably improved; the gene expression quantity of tight junction proteins Claudin-1, ZO-1 and Occludin in jejunum tissues and mucoprotein MUC2 is remarkably increased, and the contents of acetic acid, propionic acid, isobutyric acid and butyric acid in excrement are remarkably increased.

Provided are an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, a derivative comprising said antibody or antigen-binding fragment thereof, a pharmaceutical composition, and related use of said antibody or antigen-binding fragment thereof for treating, diagnosing and detecting cancers.

The invention belongs to the technical field of probiotic products, and particularly relates to lactobacillus rhamnosus JM039 as well as a composition and application thereof. The preservation number of the lactobacillus rhamnosus JM039 is GDMCC No: 64409. The lactobacillus rhamnosus JM039 is a lactobacillus rhamnosus strain. The composition is prepared from lactobacillus reuteri J1, lactobacillus gasseri JM1, lactobacillus paracasei JY062, lactobacillus paracasei with the preservation number of GDMCC.No.62990, lactobacillus plantarum JY039 and lactobacillus rhamnosus JM039, and is prepared from lactobacillus reuteri J1, lactobacillus gasseri JM1, lactobacillus paracasei JY062, lactobacillus paracasei with the preservation number of GDMCC.No.62990, lactobacillus plantarum The combined bacteria of the six probiotics can improve the levels of anti-inflammatory factors and intestinal epithelium tight junction proteins and reduce the levels of proinflammatory factors and claudin-2 mRNA, so that the intestinal microenvironment homeostasis and intestinal barrier integrity are maintained through double regulation of inflammatory factors and tight junction proteins, and necrotizing enterocolitis can be relieved.

The invention provides a bacterial strain for promoting intestinal barrier repair and nutrient absorption and application of the bacterial strain. The preservation number of bifidobacterium animalis subsp. Lactis BL-11 is CGMCC (China General Microbiological Culture Collection Center) No.20847. The bacterial strain can effectively improve the intestinal mucosa barrier structure of a mouse with colitis, promote the length of intestinal villi, increase the intestinal absorption area, promote goblet cells to secrete mucus, increase the thickness of intestinal mucosa, enhance the expression of tight junction proteins ZO-1 and Occludin of intestinal epithelial cells, reduce the levels of proinflammatory factors TNF-alpha and IL-6, improve the anti-inflammatory factor IL-10, improve the anti-inflammatory activity of the mouse with colitis and improve the anti-inflammatory activity of the mouse with colitis. Therefore, intestinal and body inflammation is relieved, and intestinal barrier repair is promoted. In addition, the homeostasis maintenance of the BL-11 strain on the intestinal barrier can also promote the absorption of nutrient substances (such as calcium).

The invention belongs to the technical field of biological medicine, and particularly relates to application of garlic polysaccharide in preparation of a product for repairing intestinal injury caused by constipation. An embodiment verifies that the garlic polysaccharide can effectively repair intestinal physical, chemical and immune barrier injuries caused by constipation, and by up-regulating expression of tight junction proteins (such as ZO-1 and Occludin) and reducing expression of Claudin-1, the garlic polysaccharide can enhance tight junction between intestinal epithelial cells and reduce intestinal permeability; besides, the garlic polysaccharide can promote secretion of intestinal mucoprotein and enhance the protection function of the intestinal mucous layer by up-regulating expression of MUC2 and MUC4 genes. The invention discloses a multi-aspect action mechanism of the garlic polysaccharide in repairing intestinal injury caused by constipation, and the garlic polysaccharide is expected to become a novel intestinal repairing agent for treating constipation and related complications thereof.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus rhamnosus MBP01 for preventing and treating irritable bowel syndrome and a composition of the lactobacillus rhamnosus MBP01. The preservation number of the lactobacillus rhamnosus MBP01 is GDMCC No: 64725, and the lactobacillus rhamnosus MBP01 has a preservation number of 64725. The MBP01 provided by the invention can improve the weight reduction trend of IBS model mice, increase the food intake and the water content of excrement, relieve the injury of colon tissues, lower the levels of IL-1beta, TNF-alpha, PAR-2 and serum corticosterone and improve the level of IL-10, and the high-concentration MBP01 can increase the expression of tight junction protein. Therefore, the MBP01 has a certain positive regulation effect on the intestinal function of the IBS model mouse, and can effectively prevent and treat the irritable bowel syndrome.

The invention belongs to the field of biological medicines, and particularly discloses application of uridine in preparation of medicines for preventing and treating ulcerative colitis, including application of uridine in preparation of medicines for preventing and treating ulcerative colitis in acute stage, application of uridine in preparation of medicines for preventing and treating ulcerative colitis in remission stage and the like. Uridine can improve the symptoms of DSS-induced acute experimental colitis model mice, has a good treatment effect, and improves the weight of the model mice; experimental results indicate that a high-dose group of uridine has a good treatment effect, the mechanism and specificity of uridine up-regulate expression and activity of colon local SIRT1 protein, further inhibit phosphorylation activation of an NF-kappa B signal channel, regulate secretion of inflammatory factors and expression of tight junction protein, repair intestinal mucosal barrier while moderately regulating immunity, and improve the immunity of a human body. The systemic inflammatory response is effectively relieved.

The invention belongs to the technical field of biological medicine, and discloses application of cornu cervi degelatinatum extract in strengthening a skin barrier. The cornu cervi degelatinatum extract disclosed by the invention can promote proliferation of HacaT cells and expression of tight junction protein Claudin-1, also has better capabilities of removing hydroxyl free radicals, DPPH free radicals and superoxide anions and an effect of promoting wound healing, and can protect a skin mechanical barrier and promote barrier injury repair. The cornu cervi degelatinatum extract has a good application prospect in preparation of drugs for promoting wound healing and products related to strengthening and toughening skin barriers, and resource development and utilization of cornu cervi degelatinatum are enriched.

Provided herein anti-human claudin 6 (CLDN6) and anti-human C5 antibodies.

The present disclosure relates to a method of promoting T cell mediated anti-tumor activity in a subject having a fibrotic tumor, the method comprising administering to the subject an anti-tight junction protein-1 antibody.

The present invention relates to bispecific antibodies against claudin 18.2 and CD3, pharmaceutical compositions comprising said bispecific antibodies, and related uses in the treatment of cancer.

Provided are combination therapies that include an inhibitor of PD-1 or PD-L1 and an antibody-drug conjugate targeting claudin 18.2.

Antibodies and compositions against Claudin 6 and uses thereof are provided.

The invention discloses application of fraxinellone as a cGAS-STING signal channel inhibitor in preparation of a medicine for treating inflammatory bowel disease, and belongs to the technical field of biological medicine. Aiming at the problem that the specific action mechanism between fraxinellone and the inflammatory bowel disease is not clear, the invention researches the specific action mechanism of fraxinellone for exerting the treatment and protection effects on the inflammatory bowel disease from the in-vivo and in-vitro aspects. Results show that the FRA can significantly inhibit the increase of the ROS level of IEC-6 cells caused by LPS, improve the mitochondrial membrane potential, significantly improve the pathological characteristics of DSS-induced mouse weight loss, DAI index increase, red, swollen and shortened colon, damaged colon tissue structure and the like, and inhibit the expression level of inflammatory factors. According to the present invention, it is found that the FRA can up-regulate the TJ tight junction protein and recover the intestinal barrier function by regulating the expression of cGAS-STING signal channel related proteins such as cGAS, STING, p-TBK1, NF-kappa B and the transcriptional level of mRNA, such that the IBD treatment effect is provided, and the basic basis is provided for the development of the new IBD treatment drug or strategy.

The application discloses a use of a solute carrier family 25A33 gene in preparation of a medicament for treating presbycusis, and the use is achieved by enhancing SLC25A33 expression on an endolymphatic vascular stripe, by maintaining mitochondrial function stability of pericyte cells around the vascular stripe, by reducing active oxygen free radical (ROS) generation, and by blocking TGFbeta / SMAD pathway-mediated pericyte differentiation, so as to protect the integrity of the blood labyrinth barrier. Animal experiments show that overexpression of SLC25A33 can significantly reduce the hearing threshold of a presbycusis model mouse, protect the structure of the blood labyrinth barrier, and improve the expression of tight junction proteins, and the SLC25A33 gene has the potential to treat presbycusis.

The present application provides a nanobody targeting Claudin18.2 and a nucleic acid sequence encoding the same. The present application also provides a multispecific antibody, a chimeric antigen receptor, an antibody conjugate comprising the Claudin18.2 nanobody, a pharmaceutical composition and a kit comprising the same, and the use of the same in the diagnosis / treatment / prevention of diseases associated with Claudin18.2 expression.

The present disclosure relates to a method of treating bile duct cancer in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an anti-tight junction protein-1 antibody.

The present invention provides a method of constructing a library of binder scaffolds (library of protein scaffolds) comprising the steps a) providing an initial polypeptide, wherein said initial polypeptide comprises or consists of a polypeptide having at least 90% identity to SEQ ID NO:1, and b) introducing diversity into copies of said initial polypeptide to form the binder scaffold library (protein scaffold library).

Described herein are methods for inhibiting a solid tumor expressing claudin-6 in a human subject, comprising administering to the human subject an effective amount of a composition comprising conjugates of a CLDN6-specific antigen-binding protein covalently bound to heterologous moieties comprising structural formula (I):whereina first plurality of the conjugates are bound to four heterologous moieties comprising structural formula (I);at least about 95% of the first plurality of conjugates are structurally homogenous; andthe effective amount is in a range of about1.0 mg of conjugate / kg weight of the subject to 10 mg of conjugate / kg weight of the subject.

The invention relates to an application of a synthetic peptide targeting CLDN12 in reduction of hepatic metastasis of pancreatic cancer. Research finds that the tight junction protein Claudin12 (CLDN12) is expressed on the surface of pancreatic cancer cells and also expressed on fibroblasts, and the CLDN12 on the fibroblasts and the CLDN12 on the pancreatic cancer cells mediate an adhesion effect through homologous interaction and guide migration and invasion of the pancreatic cancer cells. The adhesion effect of CLDN12-mediated fibroblasts and pancreatic cancer cells is blocked, and the invasion of the pancreatic cancer cells dominated by the fibroblasts can be blocked, so that the invasion and metastasis of the pancreatic cancer are reduced.

The present disclosure provides antigen binding proteins that bind to tight junction protein-6 (CLDN6). In various aspects, the antigen binding protein binds to extracellular loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells and conjugates are also provided herein. In addition, kits and pharmaceutical compositions comprising such entities are provided. Methods for preparing antigen binding proteins and methods for treating subjects with cancer are also provided.

The invention discloses a manganese-based nano-enzyme composite material as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing Mn3O4-PVP from Mn3O4 NPs and PVP10, and then loading the Mn3O4-PVP into a ZIF-8 structure in the process that Zn < 2 + > and 2-MI react to form ZIF-8, so as to obtain Mn3O4-coated ZIF-8 NPs; (2) covering the surface of the Mn3O4 ZIF-8 with HA through ion coordination, and synthesizing MZH; and (3) carrying out clathration on MZH through ES100, and synthesizing MZH coated ES100. By inhibiting a TLR4 / NF-kappa B pathway, activating an Nfr2 / Keap1 pathway and increasing expression of intestinal tight junction protein, mouse colitis induced by DSS is resisted, and symptoms of the mouse colitis are relieved.

Provided are bispecific and multi-specific antibodies that target claudin 6 (CLDN6) and 4-1BB. These antibodies, in the absence of CLDN6-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN6-expressing cells, however, these antibodies can trigger CLDN6-dependent 4-1BB signaling, leading to potent immune response to the CLDN6-expressing tumor cells.

To provide an antibody that specifically recognizes claudin 18.2 (CLDN18.2) antigen in tumor and its FFPE tissue.SOLUTION: A CLDN18.2 antibody includes heavy chain CDRs and light chain CDRs, where the heavy chain CDRs include CDR1, CDR2, and CDR3 with specific sequences, and the light chain CDRs include CDR1, CDR2, and CDR3 with specific sequences.SELECTED DRAWING: None

The invention belongs to the technical field of pharmacotherapeutics, and particularly relates to application of cryptochlorogenic acid in preparation of a medicine for preventing and treating alcoholic liver injury. The cryptochlorogenic acid has a structural formula as shown in a formula A: # imgabs0 # experiments show that the cryptochlorogenic acid can reduce liver tissue lipid metabolism disorder and reduce cell inflammation in a dose-dependent manner, reduce the levels of ALT, AST, TG, TG and LPS in animal serum, remarkably improve alcohol-induced deletion of intestinal tight junction protein, reduce intestinal leakage, and improve the bioavailability of the liver tissue. Therefore, the compound has a certain capability of treating or preventing the alcoholic liver injury, and has the potential of being developed into a medicine for treating or preventing the alcoholic liver injury.

The present invention relates to CLAUDIN-6 conjugate dosing for cancer treatment. Described herein are methods for inhibiting a Claudin-6 expressing solid tumor in a human subject comprising administering to the human subject an effective amount of a composition comprising a CLDN6 specific antigen binding protein covalently bonded to a heterologous moiety comprising structural formula (I), wherein a first plurality of the conjugates are bonded to four heterologous moieties comprising structural formula (I); at least about 95% of the first plurality of conjugates are structurally uniform; and the effective amount is in the range of about 1.0 mg conjugate / kg body weight of the subject to 10 mg conjugate / kg body weight of the subject.

The present invention provides a tight junction protein antibody H04 and its application, wherein the antibody H04 is a single-domain antibody, and the heavy chain variable region of the single-domain antibody includes CDR1, CDR2 and CDR3; the amino acid sequence of the CDR1 includes SEQ ID NO.1; the amino acid sequence of the CDR2 includes SEQ ID NO.2; and the amino acid sequence of the CDR3 includes SEQ ID NO.3. The tight junction protein antibody H04 obtained by the present invention has a higher affinity for CLDN6 and a lower affinity for CLDN9, that is, it has a higher specificity for CLDN6, and at the same time, the tumor killing effect of ADCC and CAR-T mediated by it is better, and the chimeric antigen receptor molecule constructed based on it can better mediate immune cell killing of tumors.

The present disclosure relates to kits comprising an anti claudin 18.2 antibody that are useful for assessing expression claudin 18.2 expression in a biological sample obtained from a human, e.g., a human patient having cancer.

The present invention relates to a strain of Lactobacillus johnsonii N5 and its application in preventing and treating enteritis and diarrhea. Lactobacillus johnsonii N5), was deposited in the China Center for Type Culture Collection on February 10, 2023, with the deposit number CCTCC NO: M2023104. The Lactobacillus johnsonii N5 was isolated from the fecal microorganisms of piglets resistant to heat stress-induced diarrhea. This Lactobacillus johnsonii N5 has the effect of alleviating enteritis and diarrhea, which is specifically reflected in: significantly enhancing the expression of intestinal epithelial tight junction proteins and cytoprotective heat shock protein 70, improving the immune balance of animal intestinal T cells, enhancing immune tolerance, and reducing the degree of intestinal inflammation and the occurrence of diarrheal diseases in animals. Therefore, Lactobacillus johnsonii N5 has a significant effect in preventing and treating diarrhea and related intestinal inflammatory diseases.

The present invention relates to a conjugate comprising the chemotherapeutic agent monomethyl auristatin E (MMAE) and an isolated antigen-binding protein which binds claudin-6 or an antigen-binding fragment thereof, wherein the antigen-binding protein or fragment thereof comprises: (i) HC CDR1 having a sequence GFTFSNYW (SEQ ID NO: 23), (ii) HC CDR2 having a sequence IRLKSDNYAT (SEQ ID NO: 24), (iii) HC CDR3 having a sequence XDGPPSGX (SEQ ID NO: 457), wherein X at position 1 is N and X at position 8 is S, T, A, C, or Y, (iv) LC CDR1 having a sequence ENIYSY (SEQ ID NO: 20), (v) LC CDR2 having a sequence NAK (SEQ ID NO: 21), and (vi) LC CDR3 having a sequence QHHYTVPWT (SEQ ID NO: 22); wherein the antigen-binding protein or fragment thereof is linked to a chemical structure shown in Formula I that is linked to a chemical structure shown in Formula II that is linked to a chemical structure shown in Formula III that is linked to the MMAE.